For the Inventor, By the Inventor

Enter assignee name

East Hanover, NJ, United States of America

Novartis Pharmaceuticals Corporation

USPTO Granted Patents = 19

% Expired Patents = 21.1

Trademarks = 6

Forward Citations = 201

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Heidi Lane (4 out of 7 patents)

Terence O'Reilly (4 out of 10 patents)

Jeanette Marjorie Wood (4 out of 18 patents)

4. Lili Feng (3 out of 13 patents)

5. Sven Erik Godtfredsen (3 out of 7 patents)

6. Mahavir Prashad (3 out of 29 patents)

7. Bin Hu (3 out of 8 patents)

8. Yugang Liu (3 out of 14 patents)

9. Piotr Henryk Karpinski (3 out of 23 patents)

10. Paul Allen Sutton (3 out of 18 patents)

11. Michael John Girgis (3 out of 10 patents)

12. Thomas J Blacklock (3 out of 17 patents)

13. David Roy Danville (2 out of 2 patents)

14. Elisabeth C A Brot (1 out of 8 patents)

15. Thomas Gadek (1 out of 67 patents)

19 patents: Sort by Forward Citations

1. 11642329 - Amorphous solid form of compounds containing S—N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2023-05-09),

2. 11096918 - Amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2021-08-24),

3. 11028077 - Crystalline pharmaceutical and methods of preparation and use thereof (2021-06-08),

4. 10906892 - LFA-1 inhibitor and methods of preparation and polymorph thereof (2021-02-02),

5. 9061973 - Processes for producing NEP inhibitors or prodrugs thereof (2015-06-23),

6. 8877938 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2014-11-04),

7. 8877771 - Treatment of solid tumors with rapamycin derivatives (2014-11-04),

8. 8778962 - Treatment of solid tumors with rapamycin derivatives (2014-07-15),

9. 8436010 - Treatment of solid tumors with rapamycin derivatives (2013-05-07),

10. 8410131 - Cancer treatment (2013-04-02),

11. 8324189 - Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases (2012-12-04),

12. 8183295 - Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic (2012-05-22),

13. 8119148 - Suspension comprising oxcarbazepine (2012-02-21),

14. 8052987 - Method of administering bisphosphonates (2011-11-08),

15. 7371865 - Process for the manufacture of HMG-CoA reductase inhibitors (2008-05-13),

Company Overview

Novartis Pharmaceuticals Corporation, headquartered in East Hanover, NJ, is a global healthcare company focused on the research, development, manufacturing, and marketing of innovative pharmaceuticals. The organization specializes in a wide range of therapeutic areas, including oncology, cardiology, immunology, and neuroscience. With a commitment to advancing medical science, Novartis leverages cutting-edge technologies and research methodologies to deliver transformative treatments that improve patient outcomes worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

19 Patents

#5 in East Hanover, NJ

#648 in New Jersey

#17,150 in US

#32,693 in the World

East Hanover, NJ, United States of America

Novartis Pharmaceuticals Corporation

Forward Citations = 201

44 inventors:

Heidi Lane (4 out of 7 patents)

Terence O'Reilly (4 out of 10 patents)

Jeanette Marjorie Wood (4 out of 18 patents)

4. Lili Feng (3 out of 13 patents)

5. Sven Erik Godtfredsen (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novartis Pharmaceuticals Corporation. Retrieved from https://idiyas.com/company/novartis-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…